Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

721. The cost comparison of rhythm and rate control strategies in persistent atrial fibrillation

The cost comparison of rhythm and rate control strategies in persistent atrial fibrillation Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

722. An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation

An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation Leigh J P, White R H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the clinical and economic impact of warfarin versus a second anticoagulant in hypothetical cohort of 70-year-old patients with atrial fibrillation. There was substantial variation in rates and costs of adverse events when considering all possible scenarios, but the difference in costs between the two drugs was modest. Overall, the analysis

2007 NHS Economic Evaluation Database.

723. A health economic evaluation of concomitant surgical ablation for atrial fibrillation Full Text available with Trip Pro

A health economic evaluation of concomitant surgical ablation for atrial fibrillation A health economic evaluation of concomitant surgical ablation for atrial fibrillation A health economic evaluation of concomitant surgical ablation for atrial fibrillation Lamotte M, Annemans L, Bridgewater B, Kendall S, Siebert M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness, for patients with atrial fibrillation, undergoing cardiac surgery, of high-intensity focused ultrasound-assisted surgical ablation, the classic ‘cut and sew’ maze procedure, and subsequent percutaneous ablation, in comparison with drug treatment. The maze procedure or surgical ablation were highly cost-effective

2007 NHS Economic Evaluation Database.

724. ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response Full Text available with Trip Pro

ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response Article Text Therapeutics ED use of magnesium sulphate improved rate

2006 Evidence-Based Medicine

725. Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in non-valvular atrial fibrillation Full Text available with Trip Pro

Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in non-valvular atrial fibrillation Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in non-valvular atrial fibrillation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in non-valvular atrial fibrillation Article Text

2006 Evidence-Based Medicine

726. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. (Abstract)

Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. Atrial fibrillation is the most common type of cardiac arrhythmia and a leading cause of cardiovascular morbidity, particularly stroke. The cardiac gap-junction protein connexin 40 is expressed selectively in atrial myocytes and mediates the coordinated electrical activation of the atria. We hypothesized that idiopathic atrial fibrillation has a genetic basis and that tissue-specific mutations in GJA5, the gene encoding (...) connexin 40, may predispose the atria to fibrillation.We sequenced GJA5 from genomic DNA isolated from resected cardiac tissue and peripheral lymphocytes from 15 patients with idiopathic atrial fibrillation. Identified GJA5 mutations were transfected into a gap-junction-deficient cell line to assess their functional effects on protein transport and intercellular electrical coupling.Four novel heterozygous missense mutations were identified in 4 of the 15 patients. In three patients, the mutations were

2006 NEJM

727. Review: magnesium prophylaxis after cardiac surgery reduces the risk of arrhythmia and atrial fibrillation Full Text available with Trip Pro

Review: magnesium prophylaxis after cardiac surgery reduces the risk of arrhythmia and atrial fibrillation Review: magnesium prophylaxis after cardiac surgery reduces the risk of arrhythmia and atrial fibrillation | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: magnesium prophylaxis after cardiac surgery reduces the risk of arrhythmia and atrial fibrillation Article Text Treatment Review: magnesium prophylaxis after cardiac

2006 Evidence-Based Nursing

728. Anticoagulant plus antiplatelet treatment increased the risk of bleeding in atrial fibrillation Full Text available with Trip Pro

Anticoagulant plus antiplatelet treatment increased the risk of bleeding in atrial fibrillation Anticoagulant plus antiplatelet treatment increased the risk of bleeding in atrial fibrillation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Anticoagulant plus antiplatelet treatment increased the risk of bleeding in atrial fibrillation Article Text Aetiology Anticoagulant plus antiplatelet treatment increased the risk of bleeding in atrial

2006 Evidence-Based Medicine

729. Rate control was more cost effective than rhythm control in persistent atrial fibrillation Full Text available with Trip Pro

Rate control was more cost effective than rhythm control in persistent atrial fibrillation Rate control was more cost effective than rhythm control in persistent atrial fibrillation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Rate control was more cost effective than rhythm control in persistent atrial fibrillation Article Text Economics Rate control was more cost effective than rhythm control in persistent atrial fibrillation Free David

2006 Evidence-Based Medicine

730. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. Full Text available with Trip Pro

Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. To quantify the influence of physicians' experiences of adverse events in patients with atrial fibrillation who were taking warfarin.Population based, matched pair before and after analysis.Database study in Ontario, Canada.The physicians of patients with atrial fibrillation admitted to hospital for adverse events (major haemorrhage while taking warfarin and thromboembolic strokes while (...) not taking warfarin). Pairs of other patients with atrial fibrillation treated by the same physicians were selected.Odds of receiving warfarin by matched pairs of a given physician's patients (one treated after and one treated before the event) were compared, with adjustment for stroke and bleeding risk factors that might also influence warfarin use. The odds of prescriptions for angiotensin converting enzyme (ACE) inhibitor before and after the event was assessed as a neutral control.For the 530

2006 BMJ

731. Controversies in atrial fibrillation. (Abstract)

Controversies in atrial fibrillation. Atrial fibrillation is the most common sustained cardiac arrhythmia, and contributes greatly to cardiovascular morbidity and mortality. Many aspects of the management of atrial fibrillation remain controversial. We address nine specific controversies in atrial fibrillation management, briefly focusing on the relations between mechanisms and therapy, the roles of rhythm and rate control, the definition of optimum rate control, the need for early

2006 Lancet

732. High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery (IPG184)

High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery (IPG184) Overview | High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery | Guidance | NICE High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery Interventional procedures guidance [IPG184] Published date: July 2006 Share Save Guidance The National Institute for Health and Clinical Excellence (NICE) issued (...) full guidance to the NHS in England, Wales, Scotland and Northern Ireland on High intensity focused ultrasound ablation of atrial tissue for atrial fibrillation as an associated procedure with other cardiac surgery in July 2006. In accordance with the Interventional Procedures Programme process guide, guidance on procedures with special arrangements are reviewed 3 years after publication and the procedure is reassessed if important new evidence is available. The guidance was considered

2006 National Institute for Health and Clinical Excellence - Interventional Procedures

733. Percutaneous radiofrequency ablation for atrial fibrillation (IPG168)

Percutaneous radiofrequency ablation for atrial fibrillation (IPG168) Overview | Percutaneous radiofrequency ablation for atrial fibrillation | Guidance | NICE Percutaneous radiofrequency ablation for atrial fibrillation Interventional procedures guidance [IPG168] Published date: April 2006 Share Save Guidance The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on percutaneous radiofrequency (...) catheter ablation for atrial fibrillation. and for this guidance. Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new interventional procedures. The guidance does not override the individual responsibility of healthcare professionals

2006 National Institute for Health and Clinical Excellence - Interventional Procedures

734. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. Full Text available with Trip Pro

Circumferential pulmonary-vein ablation for chronic atrial fibrillation. We conducted a randomized, controlled trial of circumferential pulmonary-vein ablation for the treatment of chronic atrial fibrillation.A total of 146 patients with a mean (+/-SD) age of 57+/-9 years who had chronic atrial fibrillation were randomly assigned to receive amiodarone and undergo two cardioversions during the first three months alone (the control group) or in combination with circumferential pulmonary-vein (...) ablation. Cardiac rhythm was assessed with daily telephonic transmissions for one year. The left atrial diameter and the severity of symptoms were assessed at 12 months.Among the 77 patients assigned to undergo circumferential pulmonary-vein ablation, ablation was repeated because of recurrent atrial fibrillation in 26 percent of patients and atypical atrial flutter in 6 percent. An intention-to-treat analysis showed that 74 percent of patients in the ablation group and 58 percent of those

2006 NEJM Controlled trial quality: uncertain

735. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. (Abstract)

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Oral anticoagulation therapy reduces risk of vascular events in patients with atrial fibrillation. However, long-term monitoring is necessary and many patients cannot achieve optimum anticoagulation. We assessed whether clopidogrel plus aspirin was non-inferior to oral (...) anticoagulation therapy for prevention of vascular events.Patients were enrolled if they had atrial fibrillation plus one or more risk factor for stroke, and were randomly allocated to receive oral anticoagulation therapy (target international normalised ratio of 2.0-3.0; n=3371) or clopidogrel (75 mg per day) plus aspirin (75-100 mg per day recommended; n=3335). Outcome events were adjudicated by a blinded committee. Primary outcome was first occurrence of stroke, non-CNS systemic embolus, myocardial

2006 Lancet Controlled trial quality: predicted high

736. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. Full Text available with Trip Pro

Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. Atrial fibrillation (AF) is associated with increased risk of mortality and cardiovascular events, particularly stroke, making prevention of new-onset AF a clinical priority. Although the presence and severity of electrocardiographic left ventricular hypertrophy (LVH) appear to predict development of AF, whether regression

2006 JAMA Controlled trial quality: predicted high

737. High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery

High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation National Institute for Health and Clinical Excellence. High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery. London: National Institute for Health and Clinical Excellence (NICE). Interventional Procedure Guidance 184. 2006 Authors' objectives This study aims to assess the current evidence on high-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery. Authors' conclusions

2006 Health Technology Assessment (HTA) Database.

738. Percutaneous occlusion of the left atrial appendage for atrial fibrillation

Percutaneous occlusion of the left atrial appendage for atrial fibrillation Percutaneous occlusion of the left atrial appendage for atrial fibrillation Percutaneous occlusion of the left atrial appendage for atrial fibrillation National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health (...) and Clinical Excellence. Percutaneous occlusion of the left atrial appendage for atrial fibrillation. London: National Institute for Health and Clinical Excellence (NICE). Interventional Procedure Guidance 181. 2006 Authors' objectives This study aims to assess the current evidence on percutaneous occlusion of the left atrial appendage for atrial fibrillation. Authors' conclusions 1 Guidance 1.1 Current evidence on the safety and efficacy of percutaneous occlusion of the left atrial appendage (LAA

2006 Health Technology Assessment (HTA) Database.

739. Atrial fibrillation: the management of atrial fibrillation

Atrial fibrillation: the management of atrial fibrillation Atrial fibrillation: the management of atrial fibrillation Atrial fibrillation: the management of atrial fibrillation National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Atrial fibrillation (...) : the management of atrial fibrillation. London: National Institute for Health and Clinical Excellence (NICE). Clinical Guideline 36. 2006 Authors' objectives The aim of this guideline is to assess the management of atrial fibrillation. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Atrial Fibrillation /diagnosis /therapy /ultrasonography /drug therapy Language Published English Country of organisation England Address for correspondence MidCity Place, 71 High Holborn, London WC1V 6NA

2006 Health Technology Assessment (HTA) Database.

740. Pulmonary vein isolation for treatment of atrial fibrillation

Pulmonary vein isolation for treatment of atrial fibrillation Pulmonary vein isolation for treatment of atrial fibrillation Pulmonary vein isolation for treatment of atrial fibrillation BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent 3 (...) years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. Pulmonary vein isolation for treatment of atrial fibrillation. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 21(1). 2006 Authors' objectives The objective of this assessment is to determine whether pulmonary vein isolation (PVI) improves health outcomes when used as an alternative to pharmacologic treatment for patients with atrial

2006 Health Technology Assessment (HTA) Database.